초록 ▼

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as c

Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

대표청구항 ▼

1. Cannabinoid infused tea leaves comprising: (a) a therapeutically effective amount of a cannabinoid;(b) a bioavailability enhancing agent comprising an edible oil comprising long chain fatty acids, wherein the bioavailability of the cannabinoid in a subject is at least 1.5 times greater than the b

1. Cannabinoid infused tea leaves comprising: (a) a therapeutically effective amount of a cannabinoid;(b) a bioavailability enhancing agent comprising an edible oil comprising long chain fatty acids, wherein the bioavailability of the cannabinoid in a subject is at least 1.5 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent; and(c) tea leaves; wherein the cannabinoid infused tea leaves are obtainable by the steps of: (i) contacting the tea leaves with an oil comprising the cannabinoid and the bioavailability enhancing agent; and(ii) dehydrating the tea leaves, thereby producing the cannabinoid infused tea leaves. 2. The cannabinoid infused tea leaves of claim 1, wherein the bioavailability of the cannabinoid in a subject is at least 3 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent. 3. The cannabinoid infused tea leaves of claim 1, wherein the bioavailability of the cannabinoid in a subject is at least 4.5 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent. 4. The cannabinoid infused tea leaves of claim 1, wherein the bioavailability enhancing agent is free of omega-6 fatty acids. 5. The cannabinoid infused tea leaves of claim 1, wherein the cannabinoid is a psychoactive cannabinoid. 6. The cannabinoid infused tea leaves of claim 1, wherein the cannabinoid is a nonpsychoactive cannabinoid. 7. The cannabinoid infused tea leaves of claim 1, wherein the bioavailability enhancing agent is a protective colloid, an edible oil or fat, and a cannabinoid taste masking agent. 8. The cannabinoid infused tea leaves of claim 7, wherein the bioavailability enhancing agent is nonfat dry milk. 9. The cannabinoid infused tea leaves of claim 1, further wherein the cannabinoid infused tea leaves are lyophilized. 10. A cannabinoid infused beverage product obtainable by the steps of: (a) contacting tea leaves with an oil comprising a cannabinoid and a bioavailability enhancing agent;(b) dehydrating the tea leaves, thereby producing cannabinoid infused tea leaves; and(c) steeping the cannabinoid infused tea leaves in a liquid, thereby producing the cannabinoid infused beverage product; wherein the cannabinoid infused tea leaves comprise: (i) a therapeutically effective amount of a cannabinoid;(ii) a bioavailability enhancing agent comprising an edible oil comprising long chain fatty acids, wherein the bioavailability of the cannabinoid in a subject is at least 1.5 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent; and(iii) tea leaves. 11. The cannabinoid infused beverage product of claim 10, wherein the bioavailability of the cannabinoid in a subject is at least 3 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent. 12. The cannabinoid infused beverage product of claim 10, wherein the bioavailability of the cannabinoid in a subject is at least 4.5 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent. 13. The cannabinoid infused beverage product of claim 10, wherein the bioavailability enhancing agent is free of omega-6 fatty acids. 14. The cannabinoid infused beverage product of claim 10, wherein the cannabinoid is a psychoactive cannabinoid. 15. The cannabinoid infused beverage product of claim 10, wherein the cannabinoid is a nonpsychoactive cannabinoid. 16. The cannabinoid infused beverage product of claim 10, wherein the bioavailability enhancing agent is a protective colloid, an edible oil or fat, and a cannabinoid taste masking agent. 17. The cannabinoid infused beverage product of claim 10, wherein the bioavailability enhancing agent is nonfat dry milk. 18. The cannabinoid infused beverage product of claim 10, further wherein the cannabinoid infused tea leaves are lyophilized.